Introduction {#section1-1533033819830751}
============

Hepatocellular carcinoma (HCC), the sixth most commonly diagnosed cancer and the third leading cause of cancer death worldwide, is among the most dangerous cancers.^[@bibr1-1533033819830751]^ Approximately 1% of deaths all around the world is related to HCC each year, of which about 50% are Chinese.^[@bibr2-1533033819830751],[@bibr3-1533033819830751]^ Current curative therapies including surgical resection, radiofrequency ablation, and liver transplantation contribute to great survival improvements for patients with early-stage HCC, while for patients with intermediate- and advanced-stage HCC who account for the majority of newly diagnosed patients, the survival remains unsatisfactory.^[@bibr4-1533033819830751],[@bibr5-1533033819830751]^

Transcatheter arterial chemoembolization (TACE) is a minimally invasive procedure that directly releases chemotherapy drug to tumor tissues with drug carriers and embolizes blood supply of tumor tissues with embolization agents.^[@bibr6-1533033819830751],[@bibr7-1533033819830751]^ The TACE is widely used as first-line therapy in patients with intermediate-stage HCC, which provides favorable treatment response and prolongs progression-free survival (PFS) as well as overall survival (OS) in patients with HCC.^[@bibr8-1533033819830751],[@bibr9-1533033819830751]^ As a novel TACE technique, drug-eluting bead TACE (DEB-TACE) contributes to better treatment response while less systemic drug toxicity compared to conventional TACE (cTACE).^[@bibr10-1533033819830751]^ CalliSpheres microspheres (CSM), the first microsphere product that is independently researched and developed in China, was launched in 2015.^[@bibr11-1533033819830751],[@bibr12-1533033819830751]^ The CSM not only loads several kinds of chemotherapeutic drugs such as doxorubicin, epirubicin, pirarubicin, gemcitabine, oxaliplatin, and irinotecan but also presents with a lot of outstanding features including high drug-loading efficiency and stable releasing profiles; besides, there are various sized CSM available (ranging from 100 to 1200 μm) in clinical practices to fully meet the needs.^[@bibr11-1533033819830751],[@bibr12-1533033819830751]^ These great properties of CSM make DEB-TACE using CSM a promising therapeutic option in treating patients with HCC. Although a few studies find that patients with HCC treated by DEB-TACE using other microspheres illuminate better efficacy and safety compared with cTACE, the difference of efficacy and safety between DEB-TACE using CSM and cTACE is still unclear, in particular, no study compares the survival benefit of DEB-TACE using CSM with cTACE in patients with HCC.^[@bibr13-1533033819830751][@bibr14-1533033819830751]-[@bibr15-1533033819830751]^ Therefore, the aim of the current study was to compare treatment response, survival, liver function, and incidence of adverse events in patients with HCC treated by DEB-TACE using CSM with patients treated by cTACE.

Materials and Methods {#section2-1533033819830751}
=====================

Patients {#section3-1533033819830751}
--------

This study was a retrospective cohort study approved by Ethics Committee of Hunan Provincial People's Hospital with approval no. 2017-09, and the written informed consents were obtained from all patients or their statutory guardians. A total of 73 patients with HCC who received DEB-TACE using CSM or cTACE treatment at Hunan Provincial People's Hospital between March 6, 2015, and September 1, 2017, were consecutively analyzed in the present study. The inclusion criteria include (1) diagnosed as primary HCC confirmed by clinical and pathological findings according to American Association for the Study of the Liver Diseases guidelines; (2) age ≥18 years old; (3) underwent DEB-TACE using CSM or cTACE treatment; and (4) medical records were complete and available. The patients were excluded if (1) they had a history of malignancies other than HCC; (2) they had severe complications; (3) they converted treatment between cTACE and DEB-TACE within 6 months; and (4) they lost follow-up without any follow-up records. In total, there were 36 patients who received DEB-TACE treatment being assigned to DEB-TACE group, and another 37 patients who received cTACE treatment were assigned to cTACE group, respectively.

Collection of Baseline Features {#section4-1533033819830751}
-------------------------------

Baseline features of all patients were collected from medical records, which included age, gender, history of hepatitis B, history of drink, history of cirrhosis, tumor location, tumor distribution, largest nodule size, portal vein invasion, hepatic vein invasion, Eastern Cooperative Oncology Group (ECOG) performance status, Child-Pugh stage, Barcelona Clinic Liver Cancer (BCLC) stage, blood routine indexes (white blood cell, red blood cell \[RBC\], absolute neutrophil count \[ANC\], hemoglobin \[Hb\], and platelet), liver function indexes (albumin \[ALB\], total protein \[TP\], total bilirubin \[TBIL\]), total bile acid \[TBA\], alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], and alkaline phosphatase \[ALP\]), renal function indexes (blood creatinine and blood urea nitrogen), tumor markers (α-fetoprotein, carcinoembryonic antigen \[CEA\], and carbohydrate antigen199 \[CA199\]), and previous treatments (cTACE, surgery, systematic chemotherapy, radiofrequency ablation, and targeted therapy).

Preoperative Treatments and Preparations {#section5-1533033819830751}
----------------------------------------

Routine treatments were performed before DEB-TACE or cTACE operation, which included analgesic treatment using pethidine and anti-infection treatments. For DEB-TACE, the CSM (Jiangsu Hengrui Medicine Co, Ltd, Jiangsu Province, China) with diameters of 100 to 300 μm or 300 to 500 μm were used as carriers and embolization agents. And the CSM were loaded with pirarubicin (60 or 80 mg, 20 mg/mL; Shenzhen Main Luck Pharmaceuticals Inc, Guangdong Province, China) and mixed with high concentration contrast agent as 1:1, 1:1.1, or 1:1.2 ratio. As for the cTACE, the chemotherapy drug solution contained pirarubicin of 60 mg or 80 mg with a concentration of 20 mg/mL, lipiodol was used as drug carriers, and polyvinyl alcohol (PVA) particles (Cook Medical LLC, Bloomington) were used as embolization agents. In addition, the 3F, 4F, and 5F microcatheters (Merit Maestro, Merit Medical System, Inc, Utah) were used in both DEB-TACE and cTACE operations.

Treatments {#section6-1533033819830751}
----------

All the DEB-TACE or cTACE procedures were conducted in the digital subtraction angiography room in our hospital. Each patient with HCC received assessment of the targeted tumor by triphasic computed tomography (CT) or magnetic resonance imaging (MRI) according to the Milan criteria.^[@bibr16-1533033819830751],[@bibr17-1533033819830751]^ The tumor supplying vessel was identified by hepatic angiography, then the femoral artery was punctured using Seldinger technique, and 3F, 4F, and 5F microcatheters were catheterized for embolization. Subsequently, the mixture of CSM for DEB-TACE or the mixture of chemotherapy drug solution, lipiodol, and PVA particles for cTACE was infused into the tumor supplying vessel through the microcatheter by pulse injection. Right after the flow of contrast agent stagnated, the embolization was stopped. After procedure, the microcatheter was pulled out, and the wound was pressed for hemostasis and then bandaged. In addition, the angiography was performed for another time to detect if there was incomplete embolization.

Postoperative Treatments {#section7-1533033819830751}
------------------------

Postprocedural treatments were as follows: All patients were told to lie on one side and extend the punctured leg for 6 to 12 hours; and patients with postoperative pain were treated by pethidine.

Evaluation of Efficacy and Safety {#section8-1533033819830751}
---------------------------------

Evaluation of treatment response was performed at month 1 (M1), M3, or M6 after DEB-TACE or cTACE treatment by enhanced CT or MRI examination. The evaluation criteria of treatment response were in conformity with the modified Response Evaluation Criteria in Solid Tumors, which were defined as follows: (1) complete response (CR): the disappearance of any intratumoral arterial enhancement in all target lesions; (2) partial response (PR): at least a 30% decrease in the sum of diameters of viable (enhancement in the arterial phase) target lesions; (3) stable disease (SD): the cases that did not qualify as a either PR or progressive disease (PD); (4) PD: the increase in diameter of targeted tumor (with arterial enhancement) ≥20% or existence of new tumor. Moreover, objective response rate (ORR) was defined as the percent of patients who achieved CR or PR, and disease control rate (DCR) was defined as the percent of patients who achieved CR, PR, or SD. Liver function indexes (ALT, AST, ALP, TBIL, ALB, TP, and TBA) which were measured at baseline (M0) and M1 after treatment and adverse events that occurred during DEB-TACE or cTACE operation and hospitalization were used to assess the safety profiles.

Patients were followed up by hospitalization or phone calls, the median follow-up duration was 12.7 months (range: 1.0-33.0 months), and the last follow-up date was March 12, 2018. Both PFS and OS were used to evaluate the survival profiles. The PFS was calculated from the time of treatment to the time of disease progression or death, and OS was calculated from the time of treatment to the time of patient's death.

Statistical Analysis {#section9-1533033819830751}
--------------------

Statistical analysis was performed using SPSS 19.0 software (SPSS Inc, Chicago) and GraphPad Prism 6.01 software (GraphPad Software Inc, San Diego). Data were expressed as count (percentage), mean (standard deviation) or median (25th-75th quantiles). Comparison between 2 groups was performed by χ^2^ test, *t* test, or Wilcoxon rank-sum test. Factors affecting ORR (M1) were determined by univariate and multivariate logistic regression analysis, and the multivariate logistic regression analysis was performed using forward stepwise (conditional) method, while the univariate and multivariate logistic regression analyses for ORR of M3 and M6 were unable to carry out due to fewer patients with treatment response assessments. Survival analysis was performed using Kaplan-Meier method and log-rank test. Factors affecting PFS and OS were determined by univariate and multivariate Cox proportional hazards regression analyses, and the multivariate Cox proportional hazards regression analysis was performed using forward stepwise (conditional LR) method. *P* value \<.05 was considered significant, and the significant results are shown in boldface.

Results {#section10-1533033819830751}
=======

Baseline Characteristics of HCC Patient log {#section11-1533033819830751}
-------------------------------------------

As depicted in [Table 1](#table1-1533033819830751){ref-type="table"}, mean ages in DEB-TACE group and cTACE group were 57.6 (11.3) and 54.9 (10.7) years, respectively (*P* = .300); the number of males and females were 31 and 5 in DEB group and 33 and 4 in cTACE group, respectively (*P* = .689). Thirty (83.3%) patients and 6 (16.7%) in DEB-TACE group as well as 30 (81.1%) patients and 7 (18.9%) in cTACE group were at Child-Pugh stages A and B, respectively (*P* = .803). As regard to BCLC stage, 9 patients (25.0%), 17 (47.2%), and 10 (27.8%) were at stages A, B, and C in DEB-TACE group, and 13 patients (35.1%), 18 (48.6%), and 6 (16.3%) were at stages A, B, and C in cTACE group, respectively (*P* = .203). Most importantly, ECOG performance score was higher in DEB-TACE group compared to cTACE group (*P* = .044); and median RBC (*P* = .020) as well as Hb (*P* = .011) were decreased while median ANC (*P* = .002) was increased in DEB-TACE group compared with cTACE group. In addition, the percent of patients with cTACE treatment history in DEB-TACE group were larger than that in cTACE group (*P* \< .001). Other baseline characteristics between 2 groups were displayed in [Table 1](#table1-1533033819830751){ref-type="table"}.

###### 

Baseline Characteristics of Patients With HCC.^a^

![](10.1177_1533033819830751-table1)

  Parameters                       DEB-TACE Group, N = 36   cTACE Group, N = 37   *P* Value
  -------------------------------- ------------------------ --------------------- ------------
  Age (years)                      57.6 (11.3)              54.9 (10.7)           .300
  Gender (male/female)             31/5                     33/4                  .689
  History of drink (n/%)           5 (13.9)                 1 (2.7)               .082
  History of HB (n/%)              18 (50.0)                26 (70.3)             .077
  History of cirrhosis (n/%)       14 (38.9)                21 (56.8)             .127
  Tumor location (n/%)                                                            .287
   Unilobar                        21 (58.3)                26 (70.3)             
   Bilobar                         15 (41.7)                11 (29.7)             
  Tumor distribution (n/%)                                                        .705
   Unifocal                        22 (61.1)                21 (56.8)             
   Multifocal                      14 (38.9)                16 (43.2)             
  Largest nodule size (cm)         5.5 (4.3-9.7)            5.6 (2.4-8.2)         .168
  Portal vein invasion (n/%)       9 (25.0)                 5 (13.5)              .213
  Hepatic vein invasion (n/%)      1 (2.8)                  1 (2.7)               .984
  ECOG performance status (n/%)                                                   **.044**
   0                               10 (27.8)                17 (45.9)             
   1                               17 (47.2)                17 (45.9)             
   2                               9 (25.0)                 2 (5.4)               
   3                               0 (0.0)                  1 (2.8)               
  Child-Pugh stage (n/%)                                                          
   A                               30 (83.3)                30 (81.1)             .803
   B                               6 (16.7)                 7 (18.9)              
  BCLC stage (n/%)                                                                .203
   A                               9 (25.0)                 13 (35.1)             
   B                               17 (47.2)                18 (48.6)             
   C                               10 (27.8)                6 (16.3)              
  Blood routine                                                                   
   WBC (×10^9^ cell/L)             5.6 (4.2-6.7)            3.9 (3.3-6.9)         .290
   RBC (×10^12^ cell/L)            3.8 (3.5-4.4)            4.6 (3.8-5.1)         **.020**
   ANC (%)                         5.6 (2.7-58.1)           2.3 (1.8-4.3)         **.002**
   Hb (g/L)                        122.0 (107.5-132.0)      134.5 (119.8-147.8)   **.011**
   PLT (× 10^9^ cell/L)            131.0 (100.5-215.5)      110.0 (66.5-213.3)    .298
  Liver function                                                                  
   ALB (g/L)                       35.6 (31.5-39.3)         35.9 (31.7-38.7)      .787
   ALB ≥1 ULN (n/%)                0/35 (0.0)               0/36 (0.0)            --
   TP (g/L)                        63.6 (58.8-67.2)         62.0 (58.7-64.3)      .462
   TP ≥1 ULN (n/%)                 0/35 (0.0)               0/36 (0.0)            --
   TBIL (μmol/L)                   16.6 (11.2-22.8)         16.3 (11.4-29.6)      .982
   TBIL ≥1 ULN (n/%)               13/35 (36.1)             13/36 (37.1)          .928
   TBA (I/L)                       8.8 (3.1-30.8)           7.1 (3.4-14.3)        .483
   TBA ≥1 ULN (n/%)                14/36 (38.9)             12/35 (34.3)          .687
   ALT (U/L)                       36.0 (23.2-46.8)         35.0 (25.2-52.5)      .756
   ALT ≥1 ULN (n/%)                15/36 (41.7)             15/35 (42.9)          .919
   AST (U/L)                       45.4 (33.0-75.0)         48.7 (28.6-89.3)      .954
   AST ≥1 ULN (n/%)                21/36 (58.3)             20/35 (57.1)          .919
   ALP (U/L)                       101.0 (81.8-173.0)       97.5 (79.5-131.8)     .488
   ALP ≥1 ULN (n/%)                12/34 (35.3)             9/34 (26.5)           .431
  Kidney function                                                                 
   BCr (μmol/L)                    62.6 (52.9-74.4)         64.8 (52.8-77.0)      .585
   BUN (mmol/L)                    4.7 (3.9-5.5)            4.5 (3.6-5.5)         .377
  Tumor markers                                                                   
   AFP (μg/L)                      46.5 (4.1-227.6)         35.0 (4.9-228.8)      .392
   CEA (μg/L)                      2.0 (1.1-3.6)            2.0 (1.2-3.5)         .935
   CA199 (kU/L)                    11.4 (6.4-36.0)          33.0 (6.5-57.5)       .230
  Previous treatments                                                             
   cTACE (n/%)                     16 (44.4)                3 (8.1)               **\<.001**
   Surgery (n/%)                   3 (8.3)                  7 (18.9)              .188
   Radiofrequency ablation (n/%)   2 (5.6)                  1 (2.7)               .539

Abbreviations: AFP, α-fetoprotein; ALB, albumin; ANC, absolute neutrophil count; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BCLC, Barcelona Clinic Liver Cancer; BCr, blood creatinine; BUN, blood urea nitrogen; CA199, carbohydrate antigen199; CEA, carcinoembryonic antigen; cTACE, conventional transarterial chemoembolization; DEB-TACE, drug-eluting bead transarterial chemoembolization; ECOG, Eastern Cooperative Oncology Group; Hb, hemoglobin; HB, hepatitis B; HCC, hepatocellular carcinoma; PLT, platelet; RBC, red blood cell; TBA, total bile acid; TBIL, total bilirubin; TP, total protein; ULN, upper limit of normal; WBC, white blood cell.

^a^ Data were presented as mean (standard deviation), median (25th-75th quantiles), or count (%). Comparison between 2 groups was determined by *t* test, Wilcoxon rank-sum test or χ^2^ test. *P* value \<.05 was considered significant, and the significant results are shown in boldface.

Treatment Response in DEB-TACE Group and cTACE Group {#section12-1533033819830751}
----------------------------------------------------

The ORR of patients was elevated in DEB-TACE group compared to cTACE group at M1 (68.0% vs 39.3%, *P* = .037), M3 (100.0% vs 62.5%, *P* = .011) as well as M6 (100.0% vs 57.1%, *P* = .029), and DCR of patients was also increased in DEB-TACE group compared with cTACE group at M3 (100.0% vs 75.0%, *P* = .037; [Table 2](#table2-1533033819830751){ref-type="table"}). As for treatment responses of nodules, there was no difference between 2 groups at M1 or M6, while at M3, ORR was elevated in DEB-TACE group compared to cTACE group (100.0% vs 62.5%, *P* \< .001; [Table 2](#table2-1533033819830751){ref-type="table"}).

###### 

Comparison of Treatment Response Between DEB-TACE Group and cTACE Group.^a^

![](10.1177_1533033819830751-table2)

                                M1           M3           M6                                                                        
  ----------------------------- ------------ ------------ ---------- ------------ ----------- ------------ ------------ ----------- ----------
  Number of assessed patients   25           28                      15           8                        9            7           
   CR                           4 (16.0)     3 (10.7)     .570       3 (20.0)     0 (0.0)     .175         3 (33.3)     1 (14.3)    .383
   PR                           13 (52.0)    8 (28.6)     .082       12 (80.0)    5 (62.5)    .363         6 (66.7)     3 (42.9)    .341
   SD                           7 (28.0)     14 (50.0)    .102       0 (0.0)      1 (12.5)    .169         0 (0.0)      1 (14.3)    .242
   PD                           1 (4.0)      3 (10.7)     .356       0 (0.0)      2 (25.0)    **.037**     0 (0.0)      2 (28.5)    .086
   ORR                          17 (68.0)    11 (39.3)    **.037**   15 (100.0)   5 (62.5)    **.011**     9 (100.0)    4 (57.1)    **.029**
   DCR                          24 (96.0)    25 (89.3)    .356       15 (100.0)   6 (75.0)    **.037**     9 (100.0)    5 (71.4)    .086
  Number of assessed nodules    46           51                      26           16                       13           9           
   CR                           8 (17.4)     4 (7.8)      .154       7 (26.9)     3 (18.8)    .131         6 (46.2)     1 (11.1)    .083
   PR                           21 (45.6)    20 (39.3)    .522       19 (73.1)    7 (43.7)    .546         6 (46.2)     6 (66.7)    .342
   SD                           17 (37.0)    27 (52.9)    .114       0 (0.0)      5 (31.3)    **.002**     1 (7.6)      2 (22.2)    .329
   PD                           0 (0.0)      0 (0.0)      --         0 (0.0)      1 (6.2)     .197         0 (0.0)      0 (0.0)     --
   ORR                          29 (63.0)    24 (47.1)    .114       26 (100.0)   10 (62.5)   **\<.001**   12 (92.3)    7 (77.8)    .329
   DCR                          46 (100.0)   51 (100.0)   --         26 (100.0)   15 (93.7)   .197         13 (100.0)   9 (100.0)   --

Abbreviations: CR, complete response; cTACE, conventional transarterial chemoembolization; DEB-TACE, drug-eluting bead transarterial chemoembolization; DCR, disease control rate; ORR, objective response rate; PD, progression disease; PR, partial response; SD, stable disease.

^a^ Data were presented as count (%). Comparison between 2 groups was determined by χ^2^ test. *P* value \<.05 was considered significant, and the significant results are shown in boldface. "--" indicated that the data were unable to be compared due to lack of events.

Univariate and Multivariate Logistic Regression Model Analyses of Factors Affecting ORR (M1) {#section13-1533033819830751}
--------------------------------------------------------------------------------------------

Univariate logistic regression model analysis was applied for analyzing factors affecting ORR (M1), which indicated that DEB-TACE was associated with higher possibility of achieving ORR (M1; *P* = .040, [Table 3](#table3-1533033819830751){ref-type="table"}). All factors were further analyzed via multivariate logistic regression model with forward stepwise (conditional) method, illustrating that DEB-TACE was an independent factor for predicting higher possibility of ORR (M1) achievement (*P* = .045, [Table 3](#table3-1533033819830751){ref-type="table"}). As to analyses for factors affecting ORR at M3 and M6, the univariate and multivariate logistic regression were not carried out due to fewer events with treatment response assessments.

###### 

Factors Affecting ORR (M1) by Logistic Regression Model Analysis.^a^

![](10.1177_1533033819830751-table3)

                                                                                Logistic Regression Model                    
  ----------------------------------------------------------------------------- --------------------------- -------- ------- ---------
  Univariate logistic regression                                                                                             
   DEB-TACE vs cTACE                                                            **.040**                    3.284    1.059   10.186
   Age ≥60 years                                                                .523                        0.701    0.235   2.087
   Male                                                                         .550                        1.773    0.271   11.584
   History of drink                                                             .906                        0.885    0.115   6.794
   History of HB                                                                .241                        1.949    0.639   5.946
   History of cirrhosis                                                         .662                        1.273    0.431   3.758
   Multifocal disease                                                           .417                        1.594    0.517   4.911
   Tumor location: bilobar                                                      .523                        0.701    0.235   2.087
   Largest nodule size ≥7 cm                                                    .564                        0.711    0.224   2.262
   Portal vein invasion                                                         .367                        2.000    0.443   9.023
   Hepatic vein invasion                                                        1.000                       0.000    0.000   --
   Higher ECOG performance status                                               .313                        0.663    0.299   1.471
   Higher Child-Pugh stage                                                      .353                        0.480    0.102   2.256
   Higher BCLC stage                                                            .484                        0.763    0.358   1.628
   Previous cTACE treatment                                                     .484                        0.763    0.358   1.628
   Previous surgery                                                             .883                        0.880    0.161   4.816
   Previous radiofrequency ablation                                             .999                        --       0.000   --
   WBC abnormal                                                                 .925                        0.944    0.289   3.083
   RBC abnormal                                                                 .140                        0.520    0.218   1.240
   ANC abnormal                                                                 .953                        0.956    0.213   4.284
   Hb abnormal                                                                  .071                        2.844    0.913   8.861
   PLT abnormal                                                                 .540                        0.686    0.205   2.295
   ALB ≥1 ULN                                                                   --                          --       --      --
   TP ≥1 ULN                                                                    --                          --       --      --
   TBIL ≥1 ULN                                                                  .168                        2.182    0.720   6.613
   TBA ≥1 ULN                                                                   .434                        0.632    0.200   1.995
   ALT ≥1 ULN                                                                   .625                        0.749    0.234   2.392
   AST ≥1 ULN                                                                   .726                        0.818    0.267   2.510
   ALP ≥1 ULN                                                                   .629                        1.333    0.415   4.281
   BCr abnormal                                                                 .152                        0.190    0.020   1.841
   BUN abnormal                                                                 .868                        1.131    0.264   4.840
   AFP abnormal                                                                 .252                        2.000    0.610   6.553
   CEA abnormal                                                                 .274                        3.579    0.364   35.233
   CA199 abnormal                                                               .716                        0.778    0.201   3.008
  Multivariate logistic regression with forward stepwise (conditional) method                                                
   DEB-TACE vs cTACE                                                            **.045**                    12.000   1.053   136.794

Abbreviations: AFP, α-fetoprotein; ALB, albumin; ALT, alanine aminotransferase; ALP, alkaline phosphatase; ANC, absolute neutrophil count; AST, aspartate aminotransferase; BCLC, Barcelona Clinic Liver Cancer; BCr, blood creatinine; BUN, blood urea nitrogen; CA199, carbohydrate antigen199; CEA, carcinoembryonic antigen; cTACE, conventional transarterial chemoembolization; DEB-TACE, drug-eluting bead transarterial chemoembolization; ECOG, Eastern Cooperative Oncology Group; Hb, hemoglobin; HB, hepatitis B; ORR, objective response rate; PLT, platelet; RBC, red blood cell; TBA, total bile acid; TBIL, total bilirubin; TP, total protein; ULN, upper limit of normal; WBC, white blood cell.

^a^ Data were presented as *P* value, odds ratio (OR), and 95% confidence interval (CI). Factors affecting ORR (M1) were determined by univariate and multivariate logistic regression analyses with forward stepwise (conditional) method. *P* value \<.05 was considered significant, and the significant results are shown in boldface. Child-Pugh stage was scored as 0 for A and 1 for B; BCLC stage was scored as 1 for stage A, 2 for stage B, and 3 for stage C; and the logistic analysis was performed based on these definitions. "--" indicated that the value was unable to be calculated due to lack of events.

Comparison of PFS and OS Between DEB-TACE Group and cTACE Group {#section14-1533033819830751}
---------------------------------------------------------------

K-M curves and log-rank tests disclosed that PFS was more prolonged in DEB-TACE group (25.1 months, 95% CI, 22.0-28.3 months) compared to cTACE group (21.8 months, 95% CI, 17.3-26.2 months; *P* = .023, [Figure 1A](#fig1-1533033819830751){ref-type="fig"}), while OS between DEB-TACE group (26.3 months, 95% CI, 23.0-29.6 months) and cTACE group (23.9 months, 95% CI, 19.2-28.6 months) was similar (*P* = .106, [Figure 1B](#fig1-1533033819830751){ref-type="fig"}).

![PFS as well as OS in DEB-TACE group and cTACE group. PFS in DEB-TACE group was longer than that in cTACE group (A), while OS between 2 groups was of no difference (B). Survival analysis was performed using Kaplan-Meier method and log-rank test. *P* value \<.05 was considered significant, and the significant results are shown in boldface. PFS indicates progression-free survival; OS, overall survival; DEB-TACE, drug-eluting bead transarterial chemoembolization; cTACE, conventional transarterial chemoembolization.](10.1177_1533033819830751-fig1){#fig1-1533033819830751}

Univariate and Multivariate Cox Proportional Hazards Regression Model Analyses of Factors Affecting PFS {#section15-1533033819830751}
-------------------------------------------------------------------------------------------------------

Univariate Cox proportional hazards regression model was applied for analyzing factors affecting PFS, which revealed that DEB-TACE was correlated with better PFS (*P* = .030), while higher Child-Pugh stage (*P* = .045), CEA abnormal (*P* = .021), and CA199 abnormal (*P* = .002) were associated with worse PFS ([Table 4](#table4-1533033819830751){ref-type="table"}). Multivariate Cox proportional hazards regression model analysis using forward stepwise (conditional LR) method was further conducted with all factors included, which suggested that DEB-TACE did not affect PFS, while CA199 abnormal (*P* = .008) was an independent factor for predicting poorer PFS ([Table 4](#table4-1533033819830751){ref-type="table"}).

###### 

Factors Affecting PFS by Cox Proportional Hazards Regression Model Analysis.^a^

![](10.1177_1533033819830751-table4)

                                                                              Cox Proportional Hazards Regression Model                    
  --------------------------------------------------------------------------- ------------------------------------------- -------- ------- ----------
  Univariate Cox regression                                                                                                                
   DEB-TACE vs cTACE                                                          **.030**                                    0.326    0.118   0.899
   Age ≥60 years                                                              .637                                        0.806    0.329   1.973
   Male                                                                       .290                                        2.964    0.397   22.148
   History of drink                                                           .694                                        1.341    0.311   5.791
   History of HB                                                              .217                                        0.575    0.238   1.385
   History of cirrhosis                                                       .658                                        1.220    0.505   2.946
   Multifocal disease                                                         .865                                        0.924    0.368   2.315
   Tumor location: bilobar                                                    .735                                        1.164    0.482   2.810
   Largest nodule size ≥7 cm                                                  .782                                        0.878    0.350   2.202
   Portal vein invasion                                                       .210                                        0.393    0.091   1.694
   Hepatic vein invasion                                                      .608                                        0.048    0.000   5337.204
   Higher ECOG performance status                                             .733                                        0.903    0.502   1.623
   Higher Child-Pugh stage                                                    **.045**                                    2.681    1.022   7.034
   Higher BCLC stage                                                          .353                                        0.751    0.410   1.375
   Previous cTACE treatment                                                   .470                                        0.668    0.223   1.998
   Previous surgery                                                           .942                                        1.047    0.307   3.574
   Previous radiofrequency ablation                                           .978                                        1.029    0.138   7.696
   WBC abnormal                                                               .864                                        1.088    0.413   2.864
   RBC abnormal                                                               .763                                        0.871    0.353   2.148
   ANC abnormal                                                               .570                                        1.400    0.438   4.472
   Hb abnormal                                                                .947                                        0.970    0.393   2.395
   PLT abnormal                                                               .407                                        1.514    0.568   4.034
   ALB ≥1 ULN                                                                 --                                          --       --      --
   TP ≥1 ULN                                                                  --                                          --       --      --
   TBIL ≥1 ULN                                                                .660                                        0.805    0.306   2.118
   TBA ≥1 ULN                                                                 .902                                        1.061    0.417   2.694
   ALT ≥1ULN                                                                  .408                                        0.665    0.253   1.749
   AST ≥1 ULN                                                                 .962                                        0.978    0.393   2.432
   ALP ≥1 ULN                                                                 .622                                        1.279    0.480   3.411
   BCr abnormal                                                               .725                                        0.696    0.092   5.253
   BUN abnormal                                                               .862                                        1.105    0.360   3.392
   AFP abnormal                                                               .253                                        0.573    0.220   1.491
   CEA abnormal                                                               **.021**                                    3.954    1.231   12.699
   CA199 abnormal                                                             **.002**                                    6.541    1.961   21.810
  Multivariate Cox regression with forward stepwise (conditional LR) method                                                                
   CA199 abnormal                                                             **.008**                                    10.058   1.820   55.598

Abbreviations: AFP, α-fetoprotein; ALB, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; ANC, absolute neutrophil count; AST, aspartate aminotransferase; BCLC, Barcelona Clinic Liver Cancer; BCr, blood creatinine; BUN, blood urea nitrogen; CA199, carbohydrate antigen199; CEA, carcinoembryonic antigen; cTACE, conventional transarterial chemoembolization; DEB-TACE, drug-eluting bead transarterial chemoembolization; ECOG, Eastern Cooperative Oncology Group; Hb, hemoglobin; HB, hepatitis B; PLT, platelet; TBA, total bile acid; TBIL, total bilirubin; TP, total protein; RBC, red blood cell; WBC, white blood cell; ULN, upper limit of normal.

^a^ Data were presented as *P* value, hazards ratio (HR), and 95% confidence interval (CI). Factors affecting progression-free survival (PFS) were determined by univariate and multivariate Cox proportional hazards regression analyses with forward stepwise (conditional LR) method. *P* value \<.05 was considered significant, and the significant results are shown in boldface. "--" indicated that the value was unable to be calculated due to lack of events.

Univariate and Multivariate Cox Proportional Hazards Regression Model Analyses of Factors Affecting OS {#section16-1533033819830751}
------------------------------------------------------------------------------------------------------

Analysis of factors affecting OS was performed by univariate Cox proportional hazards regression model, which disclosed that DEB-TACE was not associated with OS, and CEA abnormal (*P* = .042) and CA199 abnormal (*P* = .022) were correlated with worse OS ([Table 5](#table5-1533033819830751){ref-type="table"}). All factors were further analyzed in multivariate Cox proportional hazards regression model using forward stepwise (conditional LR) method, and it showed that DEB-TACE did not affect OS, while CA199 abnormal was an independent factor for predicting poorer OS (*P* = .006, [Table 5](#table5-1533033819830751){ref-type="table"}).

###### 

Factors Affecting OS by Cox Proportional Hazards Regression Model Analysis.^a^

![](10.1177_1533033819830751-table5)

                                                                              Cox Proportional Hazards Regression Model                    
  --------------------------------------------------------------------------- ------------------------------------------- -------- ------- --------
  Univariate Cox regression                                                                                                                
   DEB-TACE vs cTACE                                                          .119                                        0.397    0.124   1.267
   Age ≥60 years                                                              .601                                        1.323    0.464   3.774
   Male                                                                       .616                                        1.684    0.220   12.890
   History of drink                                                           .256                                        2.395    0.530   10.816
   History of HB                                                              .115                                        0.426    0.147   1.231
   History of cirrhosis                                                       .904                                        1.067    0.374   3.043
   Multifocal disease                                                         .941                                        0.959    0.321   2.863
   Tumor location: bilobar                                                    .420                                        1.540    0.540   4.395
   Largest nodule size ≥7 cm                                                  .668                                        1.270    0.426   3.791
   Portal vein invasion                                                       .551                                        0.633    0.141   2.838
   Hepatic vein invasion                                                      .713                                        0.048    0.000   --
   Higher ECOG performance status                                             .791                                        0.904    0.430   1.903
   Higher Child-Pugh stage                                                    .105                                        2.627    0.816   8.457
   Higher BCLC stage                                                          .729                                        0.882    0.435   1.790
   Previous cTACE treatment                                                   .514                                        0.654    0.182   2.347
   Previous surgery                                                           .633                                        1.441    0.321   6.461
   Previous radiofrequency ablation                                           .502                                        2.007    0.262   15.381
   WBC abnormal                                                               .514                                        1.451    0.474   4.436
   RBC abnormal                                                               .886                                        0.923    0.309   2.760
   ANC abnormal                                                               .645                                        1.375    0.355   5.324
   Hb abnormal                                                                .629                                        1.310    0.438   3.917
   PLT abnormal                                                               .794                                        1.171    0.357   3.839
   ALB ≥1 ULN                                                                 --                                          --       --      --
   TP ≥1 ULN                                                                  --                                          --       --      --
   TBIL ≥1 ULN                                                                .510                                        0.673    0.207   2.186
   TBA ≥1 ULN                                                                 .614                                        0.738    0.227   2.398
   ALT ≥1 ULN                                                                 .126                                        0.365    0.100   1.327
   AST ≥1 ULN                                                                 .425                                        1.616    0.498   5.249
   ALP ≥1 ULN                                                                 .962                                        0.972    0.299   3.156
   BCr abnormal                                                               .867                                        0.839    0.108   6.507
   BUN abnormal                                                               .173                                        2.303    0.693   7.652
   AFP abnormal                                                               .108                                        0.390    0.123   1.232
   CEA abnormal                                                               **.042**                                    3.982    1.052   15.081
   CA199 abnormal                                                             **.022**                                    5.060    1.264   20.246
  Multivariate Cox regression with forward stepwise (conditional LR) method                                                                
   CA199 abnormal                                                             **.006**                                    13.298   2.074   85.253

Abbreviations: AFP, α-fetoprotein; ALB, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; ANC, absolute neutrophil count; AST, aspartate aminotransferase; BCLC, Barcelona Clinic Liver Cancer; BCr, blood creatinine; BUN, blood urea nitrogen; CA199, carbohydrate antigen199; CEA, carcinoembryonic antigen; cTACE, conventional transarterial chemoembolization; DEB-TACE, drug-eluting bead transarterial chemoembolization; ECOG, Eastern Cooperative Oncology Group; Hb, hemoglobin; HB, hepatitis B; PLT, platelet; RBC, red blood cell; TBA, total bile acid; TBIL, total bilirubin; TP, total protein; ULN, upper limit of normal; WBC, white blood cell.

^a^ Data were presented as *P* value, hazards ratio (HR), and 95% confidence interval (CI). Factors affecting overall survival (OS) were determined by univariate and multivariate Cox proportional hazards regression analyses with forward stepwise (conditional LR) method. *P* value \<.05 was considered significant, and the significant results are shown in boldface. "--" indicated that the value was unable to be calculated due to lack of events.

Comparison of Liver Function Indexes (M1) and Their Changes (M1-M0) Between DEB-TACE Group and cTACE Group {#section17-1533033819830751}
----------------------------------------------------------------------------------------------------------

The percent of patients presented with TBA ≥2 upper limit of normal (ULN) at M1 in DEB-TACE group was increased compared to cTACE group (34.5% vs 7.1%, *P* = .011), while no difference of other liver function indexes between 2 groups was observed (*P*s \> .05, [Table 6](#table6-1533033819830751){ref-type="table"}). In addition, there was no difference of liver function index changes from M1 to M0 between 2 groups either (*P*s \> .05, [Figure 2](#fig2-1533033819830751){ref-type="fig"}).

###### 

Liver Function Testing at 1-Month (M1) Post-treatment.^a^

![](10.1177_1533033819830751-table6)

  Parameters           DEB-TACE Group       cTACE Group          *P* Value
  -------------------- -------------------- -------------------- -----------
  ALB (g/L)            35.4 (30.7-38.3)     35.7 (32.2-37.9)     .792
   ALB ≥1 ULN (n/%)    1/29 (3.4)           0/28 (0.0)           .322
   ALB ≥2 ULN (n/%)    0/29 (0.0)           0/28 (0.0)           --
   ALB ≥3 ULN (n/%)    0/29 (0.0)           0/28 (0.0)           --
  TP (g/L)             62.9 (60.6-70.0)     63.0 (59.5-68.5)     .708
   TP ≥1 ULN (n/%)     0/29 (0.0)           0/28 (0.0)           --
   TP ≥2 ULN (n/%)     0/29 (0.0)           0/28 (0.0)           --
   TP ≥3 ULN (n/%)     0/29 (0.0)           0/28 (0.0)           --
  TBIL (μmol/L)        17.0 (13.1-20.8)     15.1 (11.1-24.1)     .702
   TBIL ≥1 ULN (n/%)   9/29 (31.0)          11/28 (39.3)         .514
   TBIL ≥2 ULN (n/%)   3/29 (10.3)          3/28 (10.7)          .964
   TBIL ≥3 ULN (n/%)   1/29 (3.4)           1/28 (3.6)           .980
  TBA (I/L)            14.1 (5.4-33.5)      6.0 (2.0-18.3)       .125
   TBA ≥1 ULN (n/%)    16/29 (55.2)         9/28 (32.1)          .080
   TBA ≥2 ULN (n/%)    10/29 (34.5)         2/28 (7.1)           **.011**
   TBA ≥3 ULN (n/%)    7/29 (24.1)          2/28 (7.1)           .163
  ALT (U/L)            41.2 (23.8-56.9)     38.1 (24.5-52.9)     .503
   ALT ≥1 ULN (n/%)    15/29 (51.7)         11/28 (39.3)         .346
   ALT ≥2 ULN (n/%)    4/29 (13.8)          2/28 (7.1)           .413
   ALT ≥3 ULN (n/%)    1/29 (3.4)           0/28 (0.0)           .322
  AST (U/L)            50.4 (30.4-64.5)     45.3 (31.3-63.9)     .566
   AST ≥1 ULN (n/%)    19/29 (65.5)         15/28 (53.6)         .358
   AST ≥2 ULN (n/%)    6/29 (20.7)          3/28 (10.7)          .302
   AST ≥3 ULN (n/%)    2/29 (6.9)           2/28 (7.1)           .971
  ALP (U/L)            120.0 (94.0-178.0)   102.0 (80.0-140.0)   .139
   ALP ≥1 ULN (n/%)    12/27 (44.4)         9/27 (33.3)          .402
   ALP ≥2 ULN (n/%)    3/27 (11.1)          4/27 (14.8)          .685
   ALP ≥3 ULN (n/%)    0/27 (0.0)           0/27 (0.0)           --

Abbreviations: ALB, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; cTACE, conventional transarterial chemoembolization; DEB-TACE, drug-eluting bead transarterial chemoembolization; TBA, total bile acid; TBIL, total bilirubin; TP, total protein; ULN, upper limit of normal.

^a^ Data were presented as median (25th-75th quantiles) or count (%). Comparison between 2 groups was determined by Wilcoxon rank-sum test or χ^2^ test. *P* value \<.05 was considered significant, and the significant results are shown in boldface. "--" indicated that the data were unable to be compared due to lack of events.

![Liver function index change (M1-M0) in DEB-TACE group and cTACE group. All the ALB, TP, TBIL, TBA, ALT, AST, and ALP changes (M1-M0) between DEB-TACE group and cTACE group were similar. Comparison between 2 groups was performed by Wilcoxon rank-sum test. *P* value \<.05 was considered significant, and the significant results are shown in boldface. DEB-TACE indicates drug-eluting bead transarterial chemoembolization; cTACE, conventional transarterial chemoembolization; ALB, albumin; TP, total protein; TBIL, total bilirubin; TBA, total bile acid; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase.](10.1177_1533033819830751-fig2){#fig2-1533033819830751}

Comparison of Adverse Events Between DEB-TACE Group and cTACE Group {#section18-1533033819830751}
-------------------------------------------------------------------

No difference was discovered between DEB-TACE group and cTACE group regarding percentages of patients with pain (*P* = .467), nausea/vomiting (*P* = .620), or rise in blood pressure (*P* = .307) during treatment, as well as proportions of patients with pain (*P* = .515), fever (*P* = .429), or nausea/vomiting (*P* = .978) during hospitalization ([Table 7](#table7-1533033819830751){ref-type="table"}).

###### 

Adverse Events Occurred During Operation and Hospitalization.^a^

![](10.1177_1533033819830751-table7)

  Parameters                      DEB-TACE Group, N = 36   cTACE Group, N = 37   *P* Value
  ------------------------------- ------------------------ --------------------- -----------
  During treatment                                                               
   Pain (n/%)                     6 (16.7)                 4 (10.8)              .467
   Nausea/vomiting (n/%)          3 (8.3)                  2 (5.4)               .620
   Rise in blood pressure (n/%)   1 (2.7)                  0 (0.0)               .307
  During hospitalization                                                         
   Pain (n/%)                     8 (22.2)                 6 (16.2)              .515
   Fever (n/%)                    5 (13.9)                 3 (8.1)               .429
   Nausea/vomiting (n/%)          2 (5.6)                  2 (5.4)               .978

Abbreviations: cTACE, conventional transarterial chemoembolization; DEB-TACE, drug-eluting bead transarterial chemoembolization.

^a^ Data were presented as count (%). Comparison between 2 groups was determined by χ^2^ test. *P* value \<.05 was considered significant.

Discussion {#section19-1533033819830751}
==========

In the current study, we discovered that (1) DEB-TACE using CSM was associated with better treatment response and was an independent factor for predicting higher possibility of ORR achievement; (2) DEB-TACE using CSM was associated with longer PFS; (3) percent of patients with TBA ≥2ULN in DEB-TACE group was higher than that in cTACE group; and (4) no difference of adverse event incidences was found between 2 groups.

The DEB-TACE is a novel type of TACE that uses microspheres as both carriers and embolization agents.^[@bibr18-1533033819830751],[@bibr19-1533033819830751]^ A meta-analysis reveals that DEB-TACE using other microspheres (including DC bead or HepaSphere) achieves higher ORR compared with cTACE in patients with HCC, implying the better treatment response of patients with HCC to DEB-TACE over cTACE.^[@bibr14-1533033819830751]^ As for CSM, it is the first microsphere developed in China used for DEB-TACE; according to an animal experiment, it produces higher concentrations of doxorubicin in targeted tissues while lower concentrations of doxorubicin in plasma than that of cTACE.^[@bibr20-1533033819830751]^ Meanwhile, the treatment response between DEB-TACE using CSM and cTACE is also compared in patients with HCC in a retrospective cohort study, which reveals that compared to cTACE, DEB-TACE using CSM elevates ORR, DCR, and percent of patients with CR, while decreases percent of patients with PD at M3 and M6 posttreatment, indicating that patients with HCC who received DEB-TACE using CSM achieve better treatment response compared to those who received cTACE.^[@bibr15-1533033819830751]^ In the current study, similar results that ORR of both patients (at M1, M3, and M6) and nodules (at M3), as well as DCR of patients (at M3) were increased in DEB-TACE group compared with cTACE group were observed; what's more, DEB-TACE using CSM was an independent factor for predicting higher possibility of ORR (M1) achievement. The possible explanation might be that DEB-TACE displays a couple of advantages over cTACE, including more constant drug release to tumor tissues, which make DEB-TACE using CSM presents with better efficacy on reducing diameters of tumor tissues than that of cTACE.^[@bibr18-1533033819830751],[@bibr21-1533033819830751],[@bibr22-1533033819830751]^

Several studies compare the long-term survival between patients with HCC who receive DEB-TACE using other microspheres and patients who receive cTACE, some of which reveal that DEB-TACE improves survival compared with cTACE, while other studies discover that DEB-TACE does not provide survival benefits over cTACE; as to DEB-TACE using CSM, it hasn't been compared with cTACE in patients with HCC until now.^[@bibr13-1533033819830751],[@bibr23-1533033819830751][@bibr23-1533033819830751][@bibr24-1533033819830751][@bibr25-1533033819830751]-[@bibr26-1533033819830751]^ Therefore, whether DEB-TACE is more effective than cTACE in improving survival of patients with HCC remains controversial, especially for DEB-TACE using CSM. To clarify, we conducted the current study, which illustrated that PFS was more favorable in DEB-TACE group compared to cTACE group, and univariate Cox proportional hazards regression model analysis disclosed that DEB-TACE using CSM was associated with better PFS in patients with HCC. Our results might be explained by that, as previously described, CSM presents with high drug-loading efficiency, and DEB-TACE itself provides more constant drug concentration in tumor tissues than that of cTACE, which necrotizes the tumor tissue more effectively, thereby alleviates clinical symptoms while improving treatment response and subsequently prolonging PFS in patients with HCC.^[@bibr15-1533033819830751],[@bibr20-1533033819830751],[@bibr27-1533033819830751]^ In the current study, we also found that the OS between 2 groups was similar, which might be due to that the relatively small sample size decreased the statistical power, and OS was affected by so many factors that decreased the influence of TACE option (DEB-TACE vs cTACE) on OS. Meanwhile, we observed that CA199 abnormal was an independent factor for predicting poorer PFS and OS, which is also reported by many other studies.^[@bibr28-1533033819830751][@bibr29-1533033819830751]-[@bibr30-1533033819830751]^ As CA199 is highly expressed in tumor tissues in various cancers, it is reasonable for CA199 being served as a biomarker for predicting worse prognosis of patients with cancer, including patients with HCC.^[@bibr31-1533033819830751][@bibr32-1533033819830751]-[@bibr33-1533033819830751]^

As to liver function indexes, they are routinely measured for monitoring liver injury in patients with HCC who receive TACE treatment.^[@bibr15-1533033819830751],[@bibr24-1533033819830751],[@bibr34-1533033819830751]^ Most of the studies find that DEB-TACE by other microspheres is similar to or better than that of cTACE in terms of liver injury postoperation; moreover, an interesting study compared the liver function indexes between patients with HCC who receive DEB-TACE using CSM and patients who receive cTACE, which subsequently suggests that ALT, AST, and TBIL levels are decreased in patients receiving DEB-TACE using CSM compared to those receiving cTACE.^[@bibr15-1533033819830751],[@bibr24-1533033819830751],[@bibr34-1533033819830751]^ In the current study, most of liver function indexes between 2 groups were similar, indicating that DEB-TACE using CSM does not cause long-term liver injury compared with cTACE. Whereas percent of patients with TBA ≥2ULN in DEB-TACE group was higher than that in cTACE group. The possible reason might be that percent of patients with cTACE treatment history was larger in DEB-TACE group compared with cTACE group, and patients who had cTACE treatment history are more easily to have their liver injured during TACE treatment compared to those who had no cTACE treatment history; therefore, percent of patients with TBA ≥2ULN in DEB-TACE group was higher than that in cTACE group.

A few studies assess the safety of DEB-TACE using CSM in patients with HCC, which disclose that postembolization syndrome (including pain, fever, and vomiting) was the most common adverse events, most of which are mild and manageable postoperation, implying the good safety of DEB-TACE using CSM in patients with HCC.^[@bibr15-1533033819830751],[@bibr27-1533033819830751]^ Partly in line with these studies, adverse events in the current study included pain, nausea/vomiting, rise in blood pressure as well as fever, and the incidences of these adverse events between DEB-TACE group and cTACE group were of no difference, implying that DEB-TACE using CSM was equally safe compared to cTACE in treating patients with HCC. However, the incidence of pain in our study was relatively lower than that of a previous study, which might be due to the fact that (1) patients in the previous study are less severe than those in our study, including lower tumor distribution, smaller largest nodule size, and lower ECOG performance status, which meant that the pain threshold of patients in the previous study might be lower compared to those in our study; thus, the patients in previous study were easier to feel pain compared with those in our study; (2) percent of patients with surgery history in their study are higher than that in our study; therefore, patients in their study are more likely to be influenced by previous surgical wound, which also contributed to decreased pain incidence in our study compared to their study.

There were some limitations in the current study: (1) The sample size in our study was relatively small, which might result in a lower statistical power. However, considering that CSM is a novel microsphere that was launched recently (in 2015), the number of patients who received DEB-TACE treatment using CSM is very limited; besides, those patients who lost follow-up were excluded from the study due to the lack of follow-up records. Except for the small sample size, this study was a retrospective cohort study without randomization, which might cause selection bias; hence, future study with randomized design was needed. (2) Patients in this study were mainly from South China, which might also bring in selection bias. (3) As a cohort study, some baseline characteristics were different between DEB-TACE and cTACE group, which would cause compounding factors, while we applied multivariate analysis to reduce their influence. (4) A portion of patients who lost follow-up were excluded from this study due to the lack of follow-up records; thus, treatment response was not assessed in all patients at M1, M3, and M6, this might cause selection bias; what's more, the follow-up duration was relatively short, which disenabled us to compare the long-term efficacy between DEB-TACE and cTACE. Therefore, prospective study with stricter follow-up schedule and longer follow-up duration was needed in the future. (5) DEB-TACE with different diameters (100-300 and 300-500 μm) in this study might present with different efficacies and safeties, which might cause confounding bias. However, the use of CSM with different diameters was decided by patients' characteristics, which suggested that it was unsuitable for all patients with HCC to use CSM with the same diameter.

In conclusion, DEB-TACE using CSM presents with better treatment response and PFS while equal safety compared to cTACE in treating patients with HCC.
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